|
Prescribing by numbers |
(Aust Prescr 2000;23:38)
The results of clinical studies are often presented in terms of the relative risk reduction achieved with an active treatment over a control. The relative risk reduction is usually expressed as a percentage and can appear impressive but, as it is isolated from the underlying incidence of the event being prevented, it has little value in the clinical situation.
Absolute
risk reduction is the difference in event rates between active and control
groups, but it can be difficult to visualise its clinical relevance. The
reciprocal of the absolute risk reduction gives the number of patients
who need to be treated to prevent one event. This is the number needed
to treat and is a more useful measure which can be used to compare
a range of interventions.1
Calculations
| Event rate |
=
|
events
in group
number of subjects in group |
| Relative risk reduction % |
=
|
|
| Absolute risk reduction |
=
|
event rate control - event rate active |
|
Number needed to treat to prevent one event |
=
|
___________1_________
absolute risk reduction |
The results of the Helsinki heart study2 (see box) were generally presented as a reduction of 34% in the incidence of coronary heart disease with gemfibrozil treatment.
Expressing results as the number of patients who need to be treated to prevent one event (or for one patient to benefit) is much more meaningful. It can be useful when discussing treatment options with patients.
| Example Helsinki heart study Subjects: 4081 asymptomatic men aged 40-55 with dyslipidaemia (total cholesterol minus HDL >5.2 mmol/L). Treatment:
gemfibrozil 600 mg twice daily (2051 men) or matched placebo (2030
men) in a five year Results:
number of events (fatal, non-fatal myocardial infarction or cardiac
death) |
||
| Event rate placebo = |
_84_
2030 |
= 0.041 (4.1%) |
|
Event
rate active =
|
_56_
2051 |
= 0.027 (2.7%) |
|
Relative
risk reduction % =
|
|
= 34% |
|
Absolute
risk reduction =
|
0.041
- 0.027
|
= 0.014 (1.4%) |
|
Number
needed to treat for five years to prevent one event =
|
__1__ |
= 71 men |
R E F E R E N C E S
1. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect [published erratum appears in Br Med J 1995;310:1056]. Br Med J 1995;310:452-4.
2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.